Levotofisopam
Alternative Names: (S)-tofisopam; S-tofisopam; LevtofisopamLatest Information Update: 01 Sep 2015
At a glance
- Originator Vela Pharmaceuticals
- Developer Pharmos Corporation; Vela Pharmaceuticals
- Class Antigouts; Anxiolytics; Benzodiazepines; Small molecules; Uricosurics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Gout
- Discontinued CNS disorders; Vasomotor symptoms
Most Recent Events
- 12 Nov 2012 Efficacy and adverse events data from a phase II trial in Gout presented at the 76th American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2012)
- 17 May 2012 Final efficacy data from a Phase-II trial in Gout released by Pharmos Corporation
- 17 May 2012 Pharmos Corporation completes a phase-II trial in Gout in the US